Discovering the differences between craniopharyngiomas that regrow after treatment and those that don't
Molecular profiling of relapsing craniopharyngioma
Helping to develop research into antibody treatment
Investigation of ganglioside-specific receptor expression by tumour-infiltrating immune cells
Improving our understanding of how chemotherapy works in hepatoblastoma
Analysis of genome-wide 5-hydroxymethylcytosine patterns in human hepatoblastoma tumours during chemotherapy treatment
Repurposing mebendazole and albendazole for acute myeloid leukaemia
Testing the use of mebendazole and albendazole for children with acute myeloid leukaemia, and investigating how the drugs work.
Developing better and safer medicines for children with leukaemia
Screening for novel drug combinations in childhood B-cell acute lymphoblastic leukaemia
Improving treatment and reducing side effects for children with B-cell NHL
Identification of new drug targets to improve treatment options and reduce treatment-related toxicity for children diagnosed with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
Studying the genetics of leukaemia to find new treatments
Investigations into EVI1 mediated epigenetic modulation in childhood leukaemia
Developing a laboratory model of Wilms tumour to test potential new treatments
In vitro modelling of MYCN-driven poor prognosis Wilms' tumour for assessment of novel therapies
Investigating a new way of delivery drugs to the site of childhood brain tumours
Brain distribution models to select polymer-delivered drugs for the treatment of childhood brain cancers